{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:14:26Z","timestamp":1763003666771,"version":"3.45.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jtct.2023.08.018","type":"journal-article","created":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T19:41:06Z","timestamp":1692560466000},"page":"695.e1-695.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study"],"prefix":"10.1016","volume":"29","author":[{"given":"Shayna","family":"Sarosiek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4471","authenticated-orcid":false,"given":"Michelle H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe","family":"Doros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-0667","authenticated-orcid":false,"given":"Camille Vanessa","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Quillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Brauneis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-4528","authenticated-orcid":false,"given":"John Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.08.018_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtct.2023.08.018_bib0002","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ajh.26641","article-title":"Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study","volume":"97","author":"Gustine","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.08.018_bib0003","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.018_bib0004","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","article-title":"Organ responses after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"35","author":"Szalat","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.08.018_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.08.018_bib0006","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.018_bib0007","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0008","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","article-title":"Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis","volume":"63","author":"Fadia","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtct.2023.08.018_bib0009","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/bmt.2017.148","article-title":"The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution","volume":"52","author":"Arun","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jtct.2023.08.018_bib0011","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2012-09-457341","article-title":"High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center","volume":"120","author":"Tsai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.018_bib0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1525-139X.2007.00280.x","article-title":"Recognition, treatment, and prevention of propylene glycol toxicity","volume":"20","author":"Zar","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.jtct.2023.08.018_bib0013","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1378\/chest.128.3.1674","article-title":"Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study","volume":"128","author":"Wilson","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jtct.2023.08.018_bib0014","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/MJT.0b013e31824c407d","article-title":"Severe propylene glycol toxicity secondary to use of anti-epileptics","volume":"21","author":"Pillai","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.jtct.2023.08.018_bib0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1592\/phco.23.10.1094.32762","article-title":"Propylene glycol-associated renal toxicity from lorazepam infusion","volume":"23","author":"Yaucher","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtct.2023.08.018_bib0016","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/bmt.2014.120","article-title":"Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation","volume":"49","author":"Aljitawi","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0017","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicenter, open-label, safety and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0018","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.08.018_bib0019","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2023.08.018_bib0020","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.018_bib0021","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.018_bib0022","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.08.018_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jtct.2023.08.018_bib0024","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41409-018-0178-5","article-title":"Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective","volume":"53","author":"Badar","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0025","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41409-018-0388-x","article-title":"Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0026","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.018_bib0027","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2014.132","article-title":"Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis","volume":"49","author":"Freeman","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0028","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.018_bib0029","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1002\/ajh.25066","article-title":"Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"93","author":"Havasi","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:15Z","timestamp":1763003475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723015014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666636723015014"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}